Table 2.

Results of 3 GMP NanoPac® batches used for Phase 2 clinical studies and ICH compliant stability

NanoPac®	Assay (%)		Particle size (Dn50) (µ)		Particle size (Dv50) (µ)	Surface area (m2/g)
Lot number	T0	48 months	T0	48 months	48 months	T0	48 months
STV090915	100.4	98.2	0.79	0.89	2.86	29.9	28.4
STV093015	98.2	98.2	0.76	0.89	3.22	29.1	26.1
STV100715	98	98	0.83	0.85	3.2	27.9	25.9